Session Type: Poster Session (Tuesday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Tocilizumab (TCZ) has proved to be effective in the management of Giant Cell Arteritis (GCA). Based on results of the GiACTA trial, it has been approved by the FDA and the European Commission for GCA treatment. Nevertheless, almost half of the GiACTA trial patients presented a short time evolution disease.
Our aim was to evaluate the efficacy of TCZ according the time of disease evolution.
Methods: Retrospective, multicenter study of 134 patients with GCA in treatment with TCZ. A comparative study between two groups according to the time from disease diagnosis and TCZ onset was performed.
Results: Our study included 134 GCA patients. TABLE 1 summarizes a comparative study between: a) ≤ 6 months of disease evolution, and b) > 6 months of disease evolution. Non-significant difference in baseline characteristics was found. In terms of visual involvement, we observed more patients affected in the first group (≤ 6 months) (p=0.30). Analyzing clinical improvement non-significant difference was seen during follow-up. At TCZ onset, in the group of ≤ 6 months of evolution, the prednisone dose was higher with a mean dose of 31.3±16.5 mg/d vs 17.7±14.2 mg/d (p< 0.001), however, a similar reduction of corticosteroids was achieved in both groups after 6 months of follow-up. The incidence of adverse events and severe infections was similar in both groups (p=0.132 and p=672 respectively).
Conclusion: In this retrospective analysis, our results support the previously reported efficacy and safety profile of TCZ. We can conclude that TCZ can be used in GCA independently the time of disease evolution.
To cite this abstract in AMA style:Calderón-Goercke M, Loricera J, PRIETO- PENA D, Castañeda S, Aldasoro Caceres V, Villa I, Humbría A, Moriano C, Romero-Yuste S, Narváez J, Gómez-Arango C, Perez Pampín E, Melero R, Becerra-Fernández E, Revenga M, Álvarez-Rivas N, Galisteo C, Sivera F, Olivé-Marqués A, Álvarez del buergo M, Marena-Rojas L, Fernández-López C, Navarro F, Raya E, Galindez-Agirregoikoa E, Arca B, Solans-Laqué R, Conesa A, Hidalgo C, Vazquez C, Román-Ivorra J, Lluch P, Manrique S, Vela P, de Miguel E, Torres-Martín C, Nieto J, Ordas-Calvo C, salgado-Pérez E, Luna-Gómez C, Toyos-Sáenz De Miera F, Fernández-Llanio N, García A, Larena C, Aurrecoechea E, Ortiz-Sanjuán F, Corteguera M, Hernández J, González-Gay M, Blanco R. Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-tocilizumab-in-giant-cell-arteritis-independent-of-the-time-of-disease-evolution/. Accessed May 8, 2021.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-tocilizumab-in-giant-cell-arteritis-independent-of-the-time-of-disease-evolution/